ライフサイエンスコーパス: consideration should be given to

1 In obstetric hemorrhage, consideration should be given to 1 : 1 FFP :PRBC transfu

2 Strong consideration should be given to a more patient-centered

3 with evidence from other trials suggest that consideration should be given to a national programme of

4 t moderate doses may be sufficient, and that consideration should be given to a prolonged tapering co

5 Consideration should be given to adding cognitive outcom

6 Consideration should be given to adding noncoding DNA ad

7 Consideration should be given to adopting an age-calibra

8 il more long-term safety data are available, consideration should be given to avoiding anti-TNFalpha

9 In view of these findings, consideration should be given to careful screening for H

10 e limited, median survival is <6 months, and consideration should be given to clinical trials.

11 Consideration should be given to correcting cardiovascul

12 Strong consideration should be given to creating separate struc

13 Consideration should be given to developing additional s

14 e this population continues to grow and age, consideration should be given to developing consensus gu

15 ugh the separate phases of critical illness, consideration should be given to different therapeutic e

16 Serious consideration should be given to discontinuing ECMO supp

17 In carefully selected progressive lesions, consideration should be given to earlier surgical interv

18 n adverse impact on long-term mortality, and consideration should be given to either achieving CR, op

19 the next edition of the AJCC staging system, consideration should be given to eliminating the stage I

20 aluated in the emergency department, serious consideration should be given to emergent angiography an

21 nd procedure-associated infections decrease, consideration should be given to expanding surveillance

22 e, in the absence of genetic testing, strong consideration should be given to extending diagnostic se

23 g toxicity without sacrificing efficacy, and consideration should be given to fractionating or giving

24 Consideration should be given to further in vivo testing

25 Consideration should be given to further pilot studies w

26 Consideration should be given to how clinicians frame ex

27 Consideration should be given to include these criteria

28 Consideration should be given to including these values

29 A consideration should be given to increase the intraopera

30 Further consideration should be given to increased utilization o

31 f BP is more than 20/10 mm Hg above goal BP, consideration should be given to initiating therapy with

32 eceiving living unrelated renal transplants, consideration should be given to intensify initial immun

33 Strong consideration should be given to limiting large tidal vo

34 Consideration should be given to limiting the number of

35 ist or a rare monogenic disorder is present, consideration should be given to medical treatment with

36 r blood pressure and higher vasopressor use, consideration should be given to monitoring cortisol lev

37 Consideration should be given to more effective antirefl

38 Consideration should be given to more extensive promotio

39 ess of disease management in depression, and consideration should be given to more widespread impleme

40 Consideration should be given to performing a CPET in an

41 eclinical models have indicated that careful consideration should be given to predosing when using co

42 Consideration should be given to prescribing refractive

43 Therefore, strong consideration should be given to prophylactic cholecyste

44 The results also suggest that consideration should be given to raising the currently a

45 Therefore, consideration should be given to regular periodic lead t

46 Consideration should be given to revision of these mater

47 these data are confirmed in future studies, consideration should be given to routine testing of cTn

48 he initiation of glucose-lowering treatment, consideration should be given to screening all AMI patie

49 complexities of patient/nurse interactions, consideration should be given to situation and context w

50 In unresectable disease, consideration should be given to systemic chemotherapy w

51 entially useful for trachoma programmes, but consideration should be given to the co-endemicity of se

52 Consideration should be given to the development of sex-

53 in predicting athletic ability, and careful consideration should be given to the ethical issues surr

54 eparate species, and particular conservation consideration should be given to the oviparous lineage t

55 Thus, consideration should be given to the possibility that in

56 n of patients in promoting their own safety, consideration should be given to the potential influence

57 Consideration should be given to the routine inclusion o

58 Results from that study suggest that further consideration should be given to the specificity of the

59 the NPM1 genotype, and suggest that further consideration should be given to the type of DNMT3A muta

60 ated first with nerve conduction studies but consideration should be given to the use of magnetic res

61 Results here suggest that careful consideration should be given to the way in which chemic

62 Consideration should be given to this chemistry in conti

63 Consideration should be given to this novel follow-up th

64 a low chance of cure with standard HSCT and consideration should be given to treating these patients

65 Strong consideration should be given to treatment of previously

66 Consideration should be given to use of acellular pertus

67 Consideration should be given to using single agents, av

68 Consideration should be given to whether the behavior of